Mounjaro UK - £129

Mounjaro is manufactured by Eli Lilly and Company, a global pharmaceutical firm renowned for its innovative healthcare solutions. In the UK their Tirzepatide based weight loss treatment is licensed under the name Mounjaro, but in the USA it is sold under the name Zepbound.

Mounjaro contains the active ingredient Tirzepatide, which is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist. This class of drugs mimics the action of the GLP-1 hormone, which plays a crucial role in blood sugar regulation and appetite control.

Mounjaro’s active ingredient is tirzepatide, which is a long-acting GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. It enables weight loss by increasing insulin sensitivity and secretion, suppressing glucagon secretion, and slowing gastric emptying.

Mounjaro is available in several strengths. Treatment for weight loss starts at 2.5mg of tirzepatide per week, which can be gradually increased at a maximum of 2.5mg per 4 weeks, or slower depending on patient tolerance. The maximum dose is 15mg.

Mounjaro is taken once a week in the form of a “Mounjaro kwikpen” injection. The specific dosage and schedule will be determined based on individual needs and medical history. However, assuming no (or mild) side effects a fairly typical treatment plan could start as follows:

Weeks 1 – 4: 2.5mg (once a week)

Weeks 5 – 8: 5mg (once a week)

Weeks 9 – 12: 7.5mg (once a week)

Weeks 13 – 16: 10mg (once a week)

Please note that progression to stronger doses will be assessed individually and your clinician may increase your dose more slowly based on how well your body tolerates the medication.

Yes. In the UK Mounjaro was approved for weight loss and weight management by the MHRA in November 2023.  It was approved for patients over 18 suffering from obesity (defined as having a BMI of 30 or more) and also for those who are overweight (defined as having a BMI of 27 – 29) who also have other weight-related health problems. It was also approved by NICE in December 2024 for the treatment of obesity.

In the UK, Mounjaro was originally licensed for the treatment of type 2 diabetes. In 2023 the MHRA officially approved it as a weight loss medication in the UK, to be used in conjunction with a reduced-calorie diet and more physical activity. NICE also approved Mounjaro for use in the treatment of obesity in December 2024.

Mounjaro works by stimulating insulin production, which helps regulate blood sugar levels. Additionally, it slows down stomach emptying, which makes you feel fuller for a longer period and reduces overall food intake. These combined effects aid in weight loss and improve metabolic health. Also see: “Directions for Use”

Mounjaro’s active ingredient is tirzepatide. Tirzepatide is what’s known as a dual GLP-1/GIP receptor agonist. Here’s a more detailed look at how it works:

• Tirzepatide binds to GLP-1 receptors in the pancreas, enhancing insulin secretion in response to meals. This helps lower blood sugar levels.
• It also activates GIP receptors, which further enhances insulin secretion and may have additional beneficial effects on fat metabolism.
• By slowing gastric emptying, tirzepatide prolongs the feeling of fullness after eating, which reduces overall calorie intake.
• The combined action of improved insulin sensitivity, reduced appetite, and slower gastric emptying contributes to significant weight loss in patients who are prescribed Mounjaro.

For more information see the manufacturer’s Patient Information Leaflet for Mounjaro.

Clinical trials have shown that Mounjaro is effective in promoting significant weight loss. In a series of studies, participants who took Mounjaro experienced an average weight loss of up to 20% of their initial body weight over a period of 52 weeks, and up to 26% over 84 weeks (Source: nature.com). These results were significantly better compared to those who received a placebo or other weight loss medications. 

Anecdotally, many people who have taken Mounjaro also report positive outcomes beyond clinical measures. As well as substantial weight loss, patients frequently mention that their general quality of life has improved since taking Mounjaro. For instance, some users have shared that they feel more energetic, have better mobility, and experience less joint pain. Others have highlighted the psychological benefits, such as increased confidence and reduced anxiety about their health.

Direct health benefits

• Significant weight loss can lower blood sugar levels and improve insulin sensitivity, reducing the risk of developing type 2 diabetes or aiding in its management.
• Weight loss often leads to reduced blood pressure, which decreases the risk of heart disease and stroke.
• Losing weight can improve cholesterol, reducing the risk of cardiovascular diseases.

Indirect health benefits

• Weight loss can relieve stress on joints and bones, making physical activities easier and reducing the risk of osteoarthritis and injuries.
• Many users report improved sleep quality and reduced sleep apnea symptoms.
• Weight loss can lead to better mental health outcomes, including reduced depression and anxiety.

Direct lifestyle benefits

• Losing weight makes it easier to engage in physical activities, which can further enhance weight loss and overall health.
• Users often report feeling more energetic and less fatigued.
• Many users enjoy the benefit of fitting into smaller-sized clothes and having a wider variety of clothing options.

Indirect lifestyle benefits

• Weight loss can increase confidence and encourage more social interaction, improving relationships and quality of life.
• People find they can travel more comfortably and participate in activities such as hiking, biking, or even simple walks that were challenging before.
• Increased energy and improved health can lead to better focus and productivity at work.

Many reviewers felt frustrated by persistent weight gain, health concerns like prediabetes, and ineffective previous weight loss methods.

Common side effects included nausea, gastrointestinal issues, and fatigue. Many Mounjaro reviewers  recommended remedies like smaller, low-fat meals, staying hydrated, and slowly titrating doses to ease side effects.

Mounjaro reviews often mention improvements in blood sugar, cholesterol, and energy levels, along with weight loss, boosting overall health.

A large number of Mounjaro patients talk about weight loss leading to improved self-confidence, satisfaction, and motivation to continue their health journeys.

The average rating from Mounjaro reviews on drugs.com is 9/10, equivalent to 4.5* using the standard 5 star scale used by popular review platforms in the UK such as Trustpilot and Google.

26th December 2024 – Elon Musk reveals he’s taking Mounjaro (NY Post)

21st December 2024 – 500k buying weight loss jabs online because of slow NHS rollout (Telegraph)

19th December 2024 – “Superior weight loss”: Mounjaro squashing rival Wegovy (Chemist & Druggist)

15th December 2024 – EMA says now new approval needed for Mounjaro for Sleep Apnea (Sleep Review)

11th December 2024 – NICE recommends Mounjaro for overweight and obesity (Pharmafile)

7th December 2024 – Mounjaro will be available in Ireland early next year (Irish Independent)

6th December 2024 – Weight loss drug will help “so many”, say users (BBC)

5th December 2024 – obese people will have to wait for weight loss jab Mounjaro, NHS officials warn (Independent)

4th December 2024 – rise of dangerous weight loss black market sparks concern (Diabetes UK)

3rd December 2024 – Social drinkers on obesity drugs lose the taste for alcohol (NPR)

27th November 2024 – Biden proposes expanded Medicare to cover obesity drugs (Reuters)

23rd November 2024 – Whoopi Goldberg’s Mounjaro weight loss journey (The Daily Mail)

19th November 2024 – 24% of Brits would take weight-loss jabs for free on NHS (Independent)

19th November 2024 – Mounjaro shows cardiovascular benefits in patients with obesity (Yahoo)

16th November 2024 – Mounjaro now available in Belgium (Brussels Times)

15th November 2024 – 99% of Mounjaro patients remain diabetes-free after 3 years (Reuters)

13th November 2024 – Mounjaro lowers Type 2 diabetes risk in phase 3 trial (New England Journal of Medicine)

13th November 2024 – GPhC looked into 2 online pharmacies after Tik Tok influencer concerns (Chemist & Druggist)

12th November 2024 – warnings over fake Ozempic & Mounjaro being sold online (South Africa)

11th November 2024 – Mounjaro praised as “super GLP-1 RA” (Korea Biomedical Review)

10th November 2024 – Hong Kong approves “celebrity weight loss drug” (South China Morning Post)

9th November 2024 – approved weight loss drug contributed to nurse’s death (The Guardian)

28th October 2024 – Mounjaro set to be approved for use in Hong Kong by the end of 2024.

28th October 2024 – Study finds Zepbound and Mounjaro more effective for weight loss than Wegovy and Ozempic, via the Journal of the American Medical Association (JAMA)

27th October 2024 – Mounjaro manufacturer Eli Lilly to invest $5 billion to increase production capacity for Tirzepatide, the active ingredient in Mounjaro.

27th October 2024 – Weight Loss Surgeries declined by 25% in the USA between 2022 and 2023 as more patients turn to GLP-1 weight loss treatments like Mounjaro, via JAMA.

26th October 2024 – Mounjaro to launch in Denmark next week.

15th October 2024 – Health Innovation Manchester to run 5 year real-world study to measure the impact of Mounjaro on job prospects (via BBC).

2nd October 2024 – FDA removes Mounjaro from the official US medications shortage list (via FDA).

There are multiple reasons why Mounjaro may not be suitable for some people, including:

• people with a known allergy to tirzepatide or any of the ingredients in Mounjaro
• those with certain medical conditions or who are taking medications that interact negatively with Mounjaro should not use it. This includes people with a history of pancreatitis, severe gastrointestinal disease, or thyroid cancer. Mounjaro can also interact negatively with some oral contraceptives, so a barrier should also be used.
• patients taking insulin will need to seek specialist advice before taking Mounjaro.
• those under 18 years of age or over 75 years old.

Mounjaro is a prescription-only medication, and the decision to prescribe it rests with a healthcare provider. They will evaluate the patient’s overall health, medical history, and specific weight loss needs to determine eligibility. To see if you are eligible, start our free online assessment.

Depending on your individual weight loss journey, your clinician might suggest that Mounjaro weight loss treatment will be most effective when taken in combination with other weight loss methods. This may include adopting a healthy diet with fewer calories and increasing physical activity. Sustainable weight loss often requires a comprehensive approach that includes both medical treatment and lifestyle modifications.

Mounjaro can be obtained through various channels in the UK, including local and online pharmacies as well as specialist weight loss clinics. Medicspot offers next day delivery of Mounjaro across the UK subject to eligibility, and with the exception of a few of the more remote postcodes.

Mounjaro is currently available in the UK, though availability can vary between different pharmacies and regions. Medicspot has a good stock of all doses.

In the past, Mounjaro has experienced intermittent shortages due to high demand and manufacturing delays. These shortages were typically temporary, and supply was restored as production increased.

Looking forward, the supply of Mounjaro is expected to remain stable, with no significant disruptions anticipated. At Medicspot we give you the option of reserving 6 months’ treatment so that you have peace of mind that the stock is ringfenced just for you.

Recently, the manufacturer (Lilly) has expanded production capacity to meet growing demand, especially following Mounjaro’s approval in several populous regions. This expansion aims to mitigate future shortages and ensure a more consistent supply.

Investing in Mounjaro can lead to significant health benefits, potentially reducing medical expenses related to obesity-related conditions, such as diabetes, heart disease, and joint problems. Improved health can also enhance quality of life and productivity. You may also find you eat less as your appetite is suppressed, so your food spending might reduce.

Yes, Mounjaro can be purchased online from licensed pharmacies. When buying online in the UK, ensure the pharmacy is reputable and registered with the General Pharmaceutical Council (GPhC) to avoid counterfeit medications. Please note that a clinical assessment and valid prescription is required in order to obtain Mounjaro. To check if you are eligible, start your weight loss assessment now.

Mounjaro is not widely available on the NHS for weight loss treatment, but it is more widely available for the treatment of Type 2 diabetes. However, it may be prescribed in certain cases under specific criteria. Patients should consult with their GP for more information about weight loss treatments through the NHS.

With Medicspot the cost of the private prescription itself is free, and the cost of Mounjaro medication is £179 for a 4 week supply of the starting dose.

Medicspot is currently offering a discount of £50 on the first 4 week treatment course, making the cost £129, or £4.61 per day.

To qualify for a private prescription of Mounjaro in the UK, patients need a body mass index (BMI) of 30 or higher, or 27 or higher with weight-related health conditions such as type 2 diabetes or hypertension. A comprehensive consultation with a healthcare provider is required to determine individual suitability.

You’re already in the right place: Medicspot offers an online private weight loss clinic. To find out if you are eligible for a Mounjaro private prescription take our assessment.

The primary differences are speed, eligibility, availability and cost. Private clinics usually have shorter waiting times than NHS services, the criteria for prescribing in the NHS is stricter due to  limited resources in the NHS, medication is sometimes more readily available to private services, and the NHS is free, but you have to pay for the medication received via a private prescription.

Private prescriptions for Mounjaro must adhere to the same regulatory standards as other medication. Healthcare providers must ensure the medication is appropriate for the patient’s condition and that all necessary medical assessments are conducted. The prescription must be issued by a licensed medical practitioner.

Coverage for Mounjaro under private health insurance in the UK varies by provider and policy. Some insurance plans may cover the cost if it is prescribed for a medical condition like obesity or type 2 diabetes. Check your policy, and contact your insurer if in doubt.

During a consultation for a private prescription of Mounjaro, the healthcare provider will review your medical history, current medications, and overall health. They will calculate your BMI, discuss your weight loss goals, and determine if Mounjaro is appropriate for you. With Medicspot, this process all takes place via a convenient online questionnaire which is then reviewed by a clinician. If prescribed, they will explain the dosage, administration method (Mounjaro is an injectable medication), potential side effects, and schedule follow-up appointments to monitor your progress.

Before taking your first dose, your Mounjaro Kwikpen should be stored in the fridge between 2-8 degrees Centigrade. Your unused pen is safe to use through to the expiry date printed on the label if it is stored in the fridge in this way.

Once you have taken your first dose from a Mounjaro Kwikpen, you can then keep the pen at room temperature up to 30 degrees centigrade. Ensure you keep away from sources of heat e.g. a radiator, and that your Pen and needles are kept out of the reach of children at all times. 

Your used pen needs to be disposed of 30 days after you first use it, and the pen should be disposed of after you have used it for 4 of your weekly doses.

After 4 doses, your Mounjaro Kwikpen will have some liquid remaining in the clear vial section, and the plunger will not be all the way through the tube – this is normal and expected.

There are no wasted dosages, and you will receive the correct dosage of treatment each time. The Mounjaro Kwikpen will no longer prime / be dialled up to 1 when all 4 dosages have been used.

After each dose, dispose of your used needles in a sharps bin straight away. Once you have finished your 4 doses, dispose of your empty pen in your household bin after you have removed the needle.

Only the needle must be put in the sharps bin – the rest of the pen, caps etc can be disposed of in the household waste.

Arrangements for disposing of full sharps bins vary depending on where you live. Your local council or pharmacy will likely be responsible for collecting your full sharps bin. You can find out more from your local council’s website. Local councils can charge for this service, but most do not. Find your local council: https://www.gov.uk/find-local-council 

Before you start, ensure you have read the information guide and patient information leaflet that came with your medication, so that you are comfortable with both the medication and how to administer an injection.

• An online version of the Patient Information Leaflet is available here
• An online version of the Manufacturers Instructions for Use is available here
• A video from the Manufacturer on how to prepare and use the pen is available here

Below is a step by step guide to injecting a dosage from your Pen. It is important to follow the steps each time, and to ensure a new needle is used for each dosage each week.

For a version of this step by step guide with images, please visit our help page “How to use your Mounjaro KwikPen.”

• Wash your hands with soap and water.
• Remove the Mounjaro Kwikpen from the packaging and check the expiration date before use, including any additional information about the expiration date sent to you with the medication.
• Before injecting, ensure that you have a clean and dry area of skin on your stomach, thigh, or upper arm.
• Remove the cap from the Mounjaro Kwikpen
• Select a new pen needle, and pull off the paper tab from the outer needle shield. 
• Always use a new pen needle for each injection to help prevent infections and blocked needles.
• Push the capped pen needle straight onto the pen and twist the pen needle on until it is tight.
• Pull off the outer shield and keep it. This will be reused to remove the needle when you have injected your dose.
• Pull off the inner shield and dispose of it in your household bin.
• Slowly turn the dose knob until you hear 2 clicks and see the extended line in the dose window. This is the prime position. It can be corrected by turning the dose knob in either direction until the prime position lines up with the dose indicator. 
• When priming your pen, do not fully turn the dial until the 1 is showing, as this will waste significant amounts of your Pen’s total dosages. You only need to turn the dial 2 clicks until the extended line is showing on the dial.
• Hold your pen with the needle pointing up, and tap the cartridge holder gently to move the air bubbles to the top.
• Release a small amount of medicine into the air by pushing the dose knob in until it stops, then slowly count to 5 while holding the dose knob. The 0 icon must be shown in the dose window. Do not inject it into your body yet.
• Choose an injection site in your thigh or stomach (at least 5 cm from the belly button). If someone else is giving you the injection, they can also use the back of your upper arm, and make sure it is clean and dry.
• Turn the dose knob until it stops and the 1 icon is shown in the dose window, this is equal to a full dose. 
• Hold the pen firmly against the skin at a 90-degree angle and press the button on top of the pen to release the needle.
• Once the needle is inserted, hold the pen in place while pushing the button for at least 5 seconds until the 0 icon is showing in the dose window, then release the button to retract the needle.
• Carefully replace the outer needle shield, and unscrew the capped needle and dispose of it in the sharps container provided. Failing to do this before replacing the cap can lead to your pen being damaged and unusable.
• Finally, once you have unscrewed the needle, replace the pen cap and store the pen.

Mounjaro is taken once a week. A Mounjaro Kwikpen is a multi-dose, pre-filled pen and contains 4 weekly doses. So each Kwikpen lasts 28 days. One dose is to be taken each week, ideally at the same day and time each week. Do not exceed the stated dose or frequency.

See our help guide on How to use your Mounjaro Kwikpen

Need more help? Contact our team.

In the UK the MHRA has approved Mounjaro for use as an ongoing weight management medication, so there is no legal or guideline maximum limit for how long you can use Mounjaro, but if you haven’t lost sufficient weight after 3 months, your doctor may recommend another treatment.

Yes, Mounjaro is legal in the UK and has been approved for use for weight loss treatment and weight management by the MHRA. It is manufactured by Eli Lilly and Company and is only available on prescription.

Mounjaro underwent extensive clinical trials to evaluate its safety and efficacy. It was tested in multiple phases involving thousands of participants. These trials demonstrated that Mounjaro is effective in promoting weight loss and managing type 2 diabetes.

Mounjaro is safe for most people when prescribed and monitored by a healthcare professional. However, like all medications, there may be side effects. Common side effects include nausea, diarrhoea, constipation, and headaches. More serious side effects are rare but can include gastroparesis (where food doesn’t pass through the stomach properly), intestinal blockage (where the tubes of your digestive tract get blocked, which can lead to damage to the bowel wall) pancreatitis (severe inflammation of the pancreas) or gallbladder disease. Individual risk of side effects are considered as part of our clinical assessment.

In the UK Mounjaro is available by prescription and has been approved as a treatment for adults with type 2 diabetes and those needing assistance with weight loss when traditional methods have not been effective. It is particularly beneficial for individuals with a BMI of 30 or over or a BMI 27 or over who have additional weight-related health conditions.

Mounjaro has also received official approvals from other regulatory bodies internationally such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Yes you can switch from Wegovy or Saxenda to Mounjaro, but this must be done in consultation with a clinician. Our online assessment form asks you for any history of weight loss medication, so our clinicians will be able to make a decision on your individual circumstances and that is right for your weight loss journey.